Leukemic mutations in the methylation‐associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology Group

Mutations in the DNMT3A, TET2, IDH1, and IDH2 genes carry prognostic significance and occur frequently in adult acute myeloid leukemia (AML). Leukemic mutations in all four genes have recently been implicated in aberrant DNA methylation, a hallmark of neoplasia. We previously reported that IDH1 mutations were absent, whereas TET2 mutations were present in 6%, of pediatric AML patients; in the present study, we determined the prevalence of DNMT3A and IDH2 mutations in pediatric AML.

[1]  P. Guldberg,et al.  Advances in DNA methylation: 5-hydroxymethylcytosine revisited. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[2]  J. Licht,et al.  DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.

[3]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[4]  N. Heerema,et al.  TET2 SNP rs2454206 (I1762V) Correlates with Improved Survival In Pediatric Acute Myelogenous Leukemia, a Report From the Children's Oncology Group , 2010 .

[5]  L. Bullinger,et al.  TET2 Mutations In Acute Myeloid Leukemia (AML): Results on 783 Patients Treated within the AML HD98A Study of the AML Study Group (AMLSG) , 2010 .

[6]  L. Aravind,et al.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.

[7]  Yi Zhang,et al.  Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification , 2010, Nature.

[8]  R. Siebert,et al.  DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia , 2010, PloS one.

[9]  S. Raimondi,et al.  Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2010, Blood.

[10]  Manuela Zucknick,et al.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Hai Yan,et al.  Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. , 2010, Journal of the National Cancer Institute.

[12]  T. Naoe,et al.  Array-based genomic resequencing of human leukemia , 2010, Oncogene.

[13]  I. Bernstein,et al.  Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study , 2010, Leukemia.

[14]  I. Bernstein,et al.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. , 2010, Blood.

[15]  Fabien Campagne,et al.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.

[16]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[17]  H. Dombret,et al.  Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia , 2009, Cancer.

[18]  S. Meshinchi,et al.  Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia , 2009, Clinical Cancer Research.

[19]  S. Raimondi,et al.  Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. , 2009, Blood.

[20]  K. Döhner,et al.  Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. , 2008, Seminars in oncology.

[21]  C. Preudhomme,et al.  Cooperating gene mutations in acute myeloid leukemia: a review of the literature , 2008, Leukemia.

[22]  R. Arceci,et al.  The incidence and clinical significance of nucleophosmin mutations in childhood AML. , 2007, Blood.

[23]  J. Radich,et al.  Clinical implications of FLT3 mutations in pediatric AML. , 2006, Blood.

[24]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[25]  R. Daza,et al.  Genetics of the immune response: identifying immune variation within the MHC and throughout the genome , 2002, Immunological reviews.

[26]  K. Akashi,et al.  Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. , 2001, Blood.

[27]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[28]  R. Koenen,et al.  Articles on similar topics can be found in the following Blood collections Cell Adhesion and Motility (790 articles) , 2004 .